Advertisement

Topics

BMS’ Opdivo plus radiation fails to improve OS in phase 3 brain cancer trial

21:00 EDT 9 May 2019 | Pharmaceutical Business Review

The phase 3 CheckMate -498 trial assessing Opdivo plus radiation against temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM) did not achieve

The post BMS’ Opdivo plus radiation fails to improve OS in phase 3 brain cancer trial appeared first on Pharmaceutical Business review.

Original Article: BMS’ Opdivo plus radiation fails to improve OS in phase 3 brain cancer trial

NEXT ARTICLE

More From BioPortfolio on "BMS’ Opdivo plus radiation fails to improve OS in phase 3 brain cancer trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...